Tag Archives: SPEXIS

BIOTECH

Spexis provides business update and announces financial results for the first half of 2023

Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on macrocycle therapeutics for rare diseases...

Read more

BIOTECH

Spexis announces USD $2.5 million capital commitment to support the upcoming Phase 3 ColiFin® studies

Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on macrocycle therapeutics for rare diseases...

Read more

BIOTECH

Spexis announces closing of capital commitment of USD 4.5 million from SPRIM Global Investments (SGI) to enable initiation of ColiFin® Phase 3 study

Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on rare diseases and oncology, today...

Read more
This site uses cookies to offer you a better browsing experience. By browsing this website, you agree to our use of cookies.